WiseGuyRerports Introduced “Cancer Immunotherapy Market Research Report- Forecast till 2023” New Document to its Studies Database
This report analyses the current status of the global cancer immunotherapy market, outlines the key market drivers and the bases for market segmentation, and studies the future trends of this industry till 2023, using 2013 -2017 as the historical base.
The global cancer immunotherapy market was valued at USD 36.8 billion in 2016 and is estimated to reach USD 101.6 billion by 2023, at a CAGR of 14.8% during the forecast period.
The main drivers for growth in this market include an increase in the use of immunotherapy over conventional cancer medication for higher chances of survival or the growing use of a blended treatment protocol where immunotherapy is combined with other cancer treatments. Other factors include the advent and testing of newer classes of drugs which can provide better overall cancer treatment.
The major manufacturers
• F. Hoffmann-La Roche AG
• Merck & Co., Inc.
• Novartis International AG
• GlaxoSmithKline Plc.
• Amgen Inc.
• Bristol-Myers Squibb
• ELI Lilly and Company
• Celgene Corporation
• Seattle Genetics, Inc.
• Spectrum Pharmaceuticals, Inc.
Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/3496549-cancer-immunotherapy-market-research-report-forecast-till-2023
Segmentation:
The global cancer immunotherapy market can be segmented according to type of treatment, application, end user, and geographical region.
By type of treatment, this market can be split into:
- Monoclonal Antibodies
- Vaccines
- Checkpoint Inhibitors
- Cell Therapies
- Immune System Modulators
- Adoptive Cell Transfer
- Cytokines
- Others
The monoclonal antibodies segment is estimated to grow at a CAGR of 15.7% during the forecast period, followed by the vaccines and cytokines segments which are poised to grow at a CAGR of 14.8% and 12.5% respectively.
According to application, the market can be split into the following:
- Head and Neck Cancer
- Blood Cancers
- Liver Cancer
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Melanoma
- Other Cancer Types
It is expected that the lung cancer segment will continue to dominate the market during the forecast period. The factors responsible for this include a growth in the number of cigarette smokers across the world. Another segment which is expected to grow at a high rate is the breast cancer segment, especially in the developed and developing economies, owing to a higher incidence of alcohol addiction and poor rates of breastfeeding.
Based on end user, the cancer immunotherapy market can be divided into cancer research centers, hospitals, clinics, and others. Of these, the hospital segment is expected to be the highest revenue contributor during the forecast period, while the cancer research institutes segment is forecasted to grow at a CAGR of 16.1%, due to increased spending on R&D in cancer treatment options.
Regional Analysis:
North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa are the major regions for the cancer immunotherapy market across the world. North America is expected to grow at an approximate CAGR of 14.1% and reach a value of USD 105.64 billion by 2026. This could be due to increased government spending on health insurance and higher investments by cancer research institutes in R&D. On the other hand, Europe is predicted to grow at a healthy CAGR of 13.0% throughout the forecast period with the highest growth rate being witnessed in the lung cancer segment. APAC is also expected to witness a significant growth.
Industry News:
In September 2019, a research study conducted by the University of Texas Cancer Center has shown that Pegilodecakin, a first-in-class drug used presently in clinical trials, has generated positive results and may offer a potential new treatment approach for patients with non-small cell lung cancer and kidney cancer.
Complete Report Details @ https://www.wiseguyreports.com/reports/3496549-cancer-immunotherapy-market-research-report-forecast-till-2023
Table Of Content:
1 Study Coverage
2 Executive Summary
3 Breakdown Data by Manufacturers
4 Breakdown Data by Product
5 Breakdown Data by End User
6 North America
7 Europe
8 Asia Pacific
9 Central & South America
10 Middle East and Africa
11 Company Profiles
12 Future Forecast
13 Value Chain and Sales Channels Analysis
CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
